Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (111-120 of 1,111) with videos related to

Pageof 112
Sort By:
Journal of the American College of Cardiology|October 5, 2019
Reply: Ischemic Event Reduction and TriglyceridesDeepak L Bhatt, Ph Gabriel Steg, Michael Miller, et al.
European Heart Journal|August 31, 2018
The 2018 ESC-ESH guidelines for the management of arterial hypertension leave clinicians facing a dilemma in half of the patientsEmmanuelle Vidal-Petiot, Yedid Elbez, Thomas F Lüscher, et al.
European Heart Journal|September 20, 2015
Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY studyKim Fox, Ian Ford, Philippe Gabriel Steg, et al.
Journal of the American College of Cardiology|January 10, 2019
The DAPT Score in Sweden: Successful Validation, Flawed InterpretationRobert W Yeh, Dean J Kereiakes, Eric A Secemsky, et al.
American Heart Journal|October 8, 2013
Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failureKim Fox, Ian Ford, Philippe Gabriel Steg, et al.
The American Journal of Cardiology|January 10, 2002
Impact of smoking on the incidence and survival of cardiogenic shock complicating acute myocardial infarction treated with reperfusion therapyDominique Himbert, Jean-Louis Golmard, Jean-Michel Juliard, et al.
Circulation|April 20, 2018
Rediscovering the Orbit of Percutaneous Coronary Intervention After ORBITADeepak L Bhatt, Bernard J Gersh, Ph Gabriel Steg, et al.
European Heart Journal|January 13, 2009
Patients with peripheral arterial disease in the CHARISMA trialPatrice P Cacoub, Deepak L Bhatt, P Gabriel Steg, et al.
European Heart Journal|April 5, 2013
Oxygen therapy in acute coronary syndrome: are the benefits worth the risk?Mony Shuvy, Dan Atar, Philippe Gabriel Steg, et al.
Cardiovascular Therapeutics|September 3, 2011
Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian CohortZanfina Ademi, Danny Liew, Bruce Hollingsworth, et al.
Pageof 112

Showing results (111-120 of 1,111) with videos related to

Sort By:
Pageof 112
Journal of the American College of Cardiology|October 5, 2019
Reply: Ischemic Event Reduction and TriglyceridesDeepak L Bhatt, Ph Gabriel Steg, Michael Miller, et al.
European Heart Journal|August 31, 2018
The 2018 ESC-ESH guidelines for the management of arterial hypertension leave clinicians facing a dilemma in half of the patientsEmmanuelle Vidal-Petiot, Yedid Elbez, Thomas F Lüscher, et al.
European Heart Journal|September 20, 2015
Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY studyKim Fox, Ian Ford, Philippe Gabriel Steg, et al.
Journal of the American College of Cardiology|January 10, 2019
The DAPT Score in Sweden: Successful Validation, Flawed InterpretationRobert W Yeh, Dean J Kereiakes, Eric A Secemsky, et al.
American Heart Journal|October 8, 2013
Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failureKim Fox, Ian Ford, Philippe Gabriel Steg, et al.
The American Journal of Cardiology|January 10, 2002
Impact of smoking on the incidence and survival of cardiogenic shock complicating acute myocardial infarction treated with reperfusion therapyDominique Himbert, Jean-Louis Golmard, Jean-Michel Juliard, et al.
Circulation|April 20, 2018
Rediscovering the Orbit of Percutaneous Coronary Intervention After ORBITADeepak L Bhatt, Bernard J Gersh, Ph Gabriel Steg, et al.
European Heart Journal|January 13, 2009
Patients with peripheral arterial disease in the CHARISMA trialPatrice P Cacoub, Deepak L Bhatt, P Gabriel Steg, et al.
European Heart Journal|April 5, 2013
Oxygen therapy in acute coronary syndrome: are the benefits worth the risk?Mony Shuvy, Dan Atar, Philippe Gabriel Steg, et al.
Cardiovascular Therapeutics|September 3, 2011
Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian CohortZanfina Ademi, Danny Liew, Bruce Hollingsworth, et al.
Pageof 112